New funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) will support lab studies of a one-time gene therapy candidate for Parkinson’s disease. Shape Therapeutics, a U.S. company that investigates RNA-based therapies, will use the newly awarded research grant to conduct preclinical studies of its…

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to sasineprocel (ANPD001), an experimental cell therapy to treat Parkinson’s disease. The designation, given to promising regenerative therapies (treatments that aim to replace or restore disease-damaged tissue) that could substantially improve care for serious diseases, …

One evening, as I was lying in bed reading a novel, I watched my husband, Dave, out of the corner of my eye. Once again, he was having trouble getting out of bed. He couldn’t pull himself up far enough to swing his legs over the side so he could…

Low dopamine levels disrupt nerve circuits in the brain in Parkinson’s disease — but a new study indicates that different brain circuits show different, even opposite, types of changes. The study’s findings shed new light on how brain circuits are affected by Parkinson’s. The researchers said their data also suggest…

Higher blood levels of a specific ratio between two fats, called ceramides, may help identify people with Parkinson’s disease who are more likely to develop thinking and memory problems, according to a new study. A higher Cer 24:1/Cer 24:0 ratio was closely associated with worsening cognitive impairment and remained…